Risk of AAV mobilization in gene therapy

New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy. These findings, which emphasize the need for mobilization resistant AAV vectors, are reported in the peer-reviewed journal Human Gene Therapy.

The risk of rAAV mobilization has been underappreciated in the AAV research community.

“The data generated herein highlight the potential of rAAV vector production in treated patients upon subsequent wtAAV and helper virus infection,” state Matthew Hirsch, Ph.D., University of North Carolina at Chapel Hill, and coauthors. “They raise safety concerns for the treated individual and for the unintended animal and human populations in general.”

Source: Read Full Article

Related posts:
  1. Disrupted sleep in one’s 50s, 60s raises risk of Alzheimer’s disease
  2. Small reductions in blood pressure ‘slash the risk of heart disease’
  3. Gene test can predict risk of medications causing liver injury
  4. Some people have a gene that means they only need a few hours of sleep a night
Health News Comments Off on Risk of AAV mobilization in gene therapy